Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024 · Nature Medicine · 87 citations
https://doi.org/10.1038/s41591-024-03050-2
C
Claire Calmettes
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
28
Papers
208
Citations
6
h-index
5
i10-index
Claire Calmettes is an academic researcher from Agricultural University of Havana. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Acute Myeloid Leukemia Research. The author has an h-index of 6, co-authored 24 publications.
Papers by this author
worksBreakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis
2018 · Oncotarget · 18 citations
https://doi.org/10.18632/oncotarget.25477
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
2024 · Annals of Hematology · 6 citations
https://doi.org/10.1007/s00277-024-05666-3
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
2025 · The Lancet Oncology · 5 citations
https://doi.org/10.1016/s1470-2045(25)00280-3
Faire vivre et grandir une communauté de chefs de service : acte 2 en hématologie
2024 · Bulletin du Cancer · 1 citations
https://doi.org/10.1016/j.bulcan.2024.06.014
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat